New clinical and real-world evidence on Lecanemab to be presented at AAIC conference 2026

Rhea-AI Summary

BioArctic (NASDAQ Stockholm: BIOA B) announced that partner Eisai will present extensive new clinical and real-world evidence on lecanemab (Leqembi) at the AAIC 2026 conference in London, July 12–15. Highlights include subcutaneous dosing, long-term and maintenance use, at-home administration, and multiple real-world and preclinical Alzheimer’s studies.

News Market Reaction – BIOA

-1.76%

-1.76% Session close to close

In the Jun 30 session, BIOA declined 1.76%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights extensive AAIC presentations and real-world data on lecanemab, reinforc...

Analysis

This announcement highlights extensive AAIC presentations and real-world data on lecanemab, reinforcing BIOA’s Alzheimer’s franchise exposure. Investors may weigh this against the effective S-3 shelf, recent insider selling, and how prior Leqembi-related news has sometimes led to counterintuitive price moves.

Key Figures

AAIC dates: July 12–15 Plenary session time: 11:00am–12:15pm BST Maintenance dosing interval: Every four weeks +5 more

8 metrics

AAIC dates July 12–15 2026 AAIC conference in London featuring multiple lecanemab presentations

Plenary session time 11:00am–12:15pm BST July 14 plenary on community Alzheimer’s disease pathology

Maintenance dosing interval Every four weeks Real-world IV lecanemab maintenance dosing in LEADER study

Poster viewing window 7:30am–4:15pm BST Daily poster viewing period for lecanemab-related posters at AAIC

Shelf effective date March 24, 2026 Form S-3ASR shelf registration for unspecified aggregate amount of securities

Options exercise price $15.48 per share Director stock option grants reported in June 2026 Form 4 filings

Shares outstanding 44,452,734 shares Share count referenced in Schedule 13G/A ownership disclosure

Current price $24.985 Pre-news market context for BIOA on June 30, 2026

Historical Context

5 past events · Latest: Jun 22 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 22	Partnership deal	Positive	+3.4%	Lilly collaboration using BrainTransporter with upfront payment and milestones.
Jun 16	Clinical trial start	Positive	+3.3%	First participant dosed in Phase 2 QUELL-CV trial of BGE-102.
May 28	AGM outcomes	Neutral	+0.6%	AGM approvals including dividend, board elections, and issuance authorization.
May 22	Investor conferences	Neutral	-0.8%	Participation in upcoming Jefferies and Goldman Sachs healthcare conferences.
May 15	Leqembi guidance	Positive	-5.6%	Eisai projecting sharply higher FY 2026 Leqembi sales and royalties to BIOA.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

BIOA has generally reacted positively to partnership and clinical updates, with one notable selloff following strong Leqembi revenue guidance.

Key Terms

subcutaneous, maintenance dosing, phase 3, tau pet, +2 more

6 terms

subcutaneous medical

"data on its subcutaneous formulation, long-term use across diverse patient"

Subcutaneous means situated or applied just beneath the skin. In finance, the term can describe processes or investments that are hidden or not immediately visible, much like something placed under the skin that isn't easily seen from the outside. Recognizing subcutaneous activities helps investors understand underlying factors that may influence markets or asset values over time.

maintenance dosing medical

"results on maintenance dosing with IV treatment every four weeks and the"

Maintenance dosing is the ongoing, steady amount of a drug a patient takes after initial treatment to keep its effects stable over time. For investors, it matters because predictable, long-term dosing drives recurring sales, influences pricing and insurance coverage, and affects safety and adherence profiles—like a subscription model that determines how often and how much customers keep paying.

phase 3 medical

"Presentations on the Phase 3 AHEAD 3-45 study in preclinical Alzheimer's"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

tau pet medical

"Presentation: Tau PET Change in CLARITY-AD (Abstract ID 13333)"

Tau PET is a brain imaging test that uses a tiny radioactive tracer and a PET scanner to show deposits of the tau protein, which accumulate in Alzheimer’s and related diseases. It matters to investors because it can identify the patients most likely to benefit from a drug, provide a measurable way to judge treatment effects in clinical trials, and influence the commercial and regulatory prospects for diagnostics and therapies—like a camera that lets developers and doctors see whether a treatment is hitting its target.

amyloid-related imaging abnormality medical

"Differential Costs Of Amyloid-related Imaging Abnormality Management Between"

Amyloid-related imaging abnormality (ARIA) is an MRI-detected change in the brain—typically swelling or small areas of bleeding—that can occur in people treated with therapies that remove or target amyloid protein. Investors should care because ARIA is a safety signal that can limit a drug’s use, trigger stricter monitoring or labeling, affect regulatory approval, and influence market adoption and costs; think of it as a car’s warning light that can force extra inspections or repairs.

monoclonal antibodies medical

"Treatment Benefits of Anti-amyloid Monoclonal Antibodies In Early Alzheimer's"

Monoclonal antibodies are lab-made proteins designed to bind a single, specific target on cells or viruses, like identical keys cut to fit one lock. They are used as medicines, tests, or targeted delivery tools and can precisely block or mark disease processes. Investors care because they can become high-value drugs with large sales, long patent protection, and binary risks tied to clinical trial results, regulatory approval, manufacturing scale and pricing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

STOCKHOLM, June 30, 2026 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ STOCKHOLM: BIOA B) partner Eisai will present new clinical and real-world evidence on lecanemab (Leqembi®) at the Alzheimer's Association International Conference (AAIC) in London, July 12-15, including data on its subcutaneous formulation, long-term use across diverse patient groups, maintenance dosing, and at-home administration.

BioArctic will also participate in the Plenary Session "Prevalence of Alzheimer's Disease Pathology in the Community," taking place on 14 July (11:00am to 12:15pm BST). In a presentation called "Outcomes of Clinical Progression for Clinical Trials of People with Neuronal Synucleinopathy with Cognitive Impairment", strategies for assessing clinical progression in people with cognitive impairment related to α-synuclein pathology will be discussed, primarily across Parkinson's disease (PD), Parkinson's disease dementia (PDD), and dementia with Lewy bodies (DLB).

Key oral lecanemab presentations at AAIC

• Subcutaneous treatment data: On Sunday, July 12, as part of the "Developing Topics Session: Lecanemab Subcutaneous Formulation in Early Alzheimer's Disease: Emerging Clinical Evidence and Practical Use Considerations" (4:15-5:45pm BST), emerging clinical evidence and practical use considerations for the subcutaneous formulation of lecanemab will be presented, including clinical trial and real-world patient experience.
• LEADER study – real-world evidence from US clinical practice: On Tuesday, July 14, as part of the "Featured Research Session: Lecanemab Three Years Post Approval: A Comprehensive Multicenter, Real-World, Retrospective Study (LEADER) in Diverse US Clinical Settings"
  (4:15-5:45pm BST), data from the LEADER study evaluating real-world lecanemab use in diverse US clinical settings three years post-approval, will be presented. It will include results on maintenance dosing with IV treatment every four weeks and the first reported findings of at-home subcutaneous administration.  
• Preclinical Alzheimer's Disease: Presentations on the Phase 3 AHEAD 3-45 study in preclinical Alzheimer's Disease will highlight progress of the trial, including updates on participant retention and engagement.

Additional oral presentations

Presentation date and time (BST)	Presentation title and abstract number
July 12 2:00 – 3:30pm	Developing Topics Session 1-23-FRSB Developing Topics in Amyloid Targeting Therapies: Global Perspectives from Trials to Real World Evidence. Presentation: Treatment Actions following ARIA in Patients Treated with Lecanemab: Evidence from a Post-Marketing Observational Study in Japan (Abstract ID TBA)
July 13  8:00 – 8:45am	Developing Topic Session #2-6-DEV: Developing Topics in Amyloid Targeting Therapies and Real-World Outcomes. Presentation: Sex-Based Outcomes of Lecanemab in Early Alzheimer's Disease: A Comprehensive Multicenter, Real-World, Retrospective Study (LEADER) (Abstract ID TBA)
July 13   9:00 – 10:30am	Featured Research Session #2-15-FRS-A: External Controls In Alzheimer's Clinical Trials: How Far Away Are We?  Presentation: External Controls in Open-Label Extensions: Insights from Clarity AD (Abstract ID 982)
July 14  8:00 – 8:45am	Developing Topics Session #3-4-DEV: Developing Topics in Pathological Changes Resulting from Amyloid Targeting Treatment in Alzheimer's Disease. Presentation: Broad Modulation of Core Tau Biomarkers, Including pTau205 Following Lecanemab Treatment (Abstract ID 13515)
July 14  8:00 – 8:45am	Developing Topics Session #3-4-DEV: Developing Topics in Pathological Changes Resulting from Amyloid Targeting Treatment in Alzheimer's Disease. Presentation: Tau PET Change in CLARITY-AD (Abstract ID 13333)
July 14 8:00 – 8 :45am	Developing Topics Session #3-3-DEV: Developing Topics in Factors Affecting Fluid Biomarkers. Presentation: Racial And Ethnic Differences in %p-tau217 Associations with Cognitive Performance and Amyloid PET In Preclinical AD (Abstract ID 13712)
July 14 9:00 – 10:30am	Featured Research Session #3-15-FRS-A: Anti-Amyloid Therapy: Real World Experience. Presentation: Lecanemab Clinical Practice: A Multicenter, Surveillance Safety Study from the ALZ-NET Registry (Abstract ID 6202)

Poster presentations on lecanemab
Poster viewing time is set from 7:30am – 4:15pm BST on the date of presentation

Presentation date	Presentation title and abstract number
July 12	Characterization and Utilization Assessment of a Centrally Supported Ride-Share Service Implemented in a Multisite Preclinical Alzheimer's Clinical Trial (Abstract ID TBA)
	Long-Term Persistence and Patient Characteristics for Intravenous and Subcutaneous Lecanemab in Real-World Use in the United States (Abstract ID 7344)
	Retrospective Case Series of Real-world Clinical and Patient-reported Outcomes with Lecanemab (Abstract ID 9480)
	Retrospective Observational Cohort Study of Real-world Clinical and Patient-reported Outcomes with Lecanemab (Abstract ID 9882)
July 13	Subcutaneous Lecanemab Administration in an Alzheimer's Disease Treatment Center: Real-World Clinical Outcomes and Patient Experiences  (Abstract ID 1556)
	INITIATE-SC: A Multicenter Real-World Study of Subcutaneous Lecanemab Initiation in Early Alzheimer's Disease (Abstract ID 13568)
	Continued or Time-limited Treatment Benefits of Anti-amyloid Monoclonal Antibodies In Early Alzheimer's Disease (Abstract ID 13738)
	Early Alzheimer's Disease Treated with Lecanemab: A Real-World, Retrospective Analysis from a Colorado Neurological Clinic  (Abstract ID 12904)
	Communicating Participant Milestones to Enhance Trial Engagement and Retention in a Preclinical Alzheimer's Trial (Abstract ID 9159)
	Initial Real-World Experience in Using Lecanemab in Hong Kong: Safety and Preliminary PET CT Data (Abstract ID 11962)
July 14	Real-World Lecanemab Treatment in Early Alzheimer's Disease: A Retrospective Dementia Clinic Case Series Review from a Geriatric Medicine Clinical Practice (Abstract ID 1947)
July 15	A Time and Motion and Patient Satisfaction Study of Subcutaneous Injection of Lecanemab for Patients with Early Alzheimer's Disease (Abstract ID 13637)
	Differential Costs Of Amyloid-related Imaging Abnormality Management Between Anti-amyloid Treatments: Estimates Based On A Delphi Panel (Abstract ID 9345)
	VISION AD-JP: A Prospective Multicenter Real-world Study of Japanese Patients with Early Alzheimer's Disease Treated with Lecanemab (Abstract ID 13235)
	Real-World Outcomes with Lecanemab Treatment in a New England Alzheimer's Disease Center (Abstract ID 1949)
	Estimating the Economic Impact of Delayed Alzheimer's Disease Progression with Lecanemab (Abstract ID 9889)
	Economic, Health, and Quality-of-Life Burden on Caregivers and Study Partners of Lecanemab-Treated Individuals with Alzheimer's Disease (Abstract ID 6169)

Eisai-Sponsored Symposium 

Symposium is intended for HCPs only

Presentation date and time	Title
July 14 12:30 – 1:45pm	Early Intervention in Alzheimer's Disease: Building the Evidence from Pathology to Practice

The information was released for public disclosure, through the agency of the contact person below, on June 30, 2026, at 8am CET.

For further information, please contact: 
Oskar Bosson, Chief Investor Relations & Communications Officer
E-mail: oskar.bosson@bioarctic.com
Telephone: +46 704 107 180

Jenny Ljunggren, External Communications and Investor Relations Manager
E-mail: jenny.ljunggren@bioarctic.com
Telephone: +46 76 013 86 08

About Leqembi^® (lecanemab)

Leqembi is the result of a strategic research alliance between BioArctic and Eisai. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ).

Leqembi is approved in 53 countries and is under regulatory review in 6 countries. Following the initial phase with treatment every two weeks for 18 months, intravenous (IV) maintenance dosing with treatment every four weeks is approved in 8 countries, including the United Kingdom, China, the US and Japan, and applications have been filed in 12 countries and regions. In the US, Leqembi Iqlik™ is approved for subcutaneous dosing with an autoinjector for maintenance treatment of early Alzheimer's disease. In November 2025, a new drug application for subcutaneous formulation of Leqembi was submitted in Japan. In December 2025, Leqembi was included in the "Commercial Insurance Innovative Drug List", recently introduced by the National Healthcare Security Administration (NHSA) of China. In January 2026, Eisai's supplemental Biologics License Application (sBLA) regarding a subcutaneous starting dose with Leqembi Iqlik was granted Priority Review by the US FDA. The sBLA has been assigned an extended PDUFA date of August 24, 2026. In January 2026, the Biologics License Application for subcutaneous formulation of Leqembi was accepted in China and in February, the application was designated for priority review.

Since July 2020, Eisai's Phase 3 clinical study (AHEAD 3-45) with lecanemab in individuals with preclinical Alzheimer's disease meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. The study was fully recruited in October 2024. AHEAD 3-45 is a four-year study conducted as a public-private partnership between Eisai, Biogen and the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in Alzheimer's disease and related dementias in the US, funded by the National Institute on Aging, part of the National Institutes of Health. Since January 2022, the Tau NexGen clinical study for Dominantly Inherited Alzheimer's disease (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, is ongoing and includes lecanemab as the backbone anti-amyloid therapy.

About the collaboration between BioArctic and Eisai

Since 2005, BioArctic has a long-term collaboration with Eisai regarding the development and commercialization of drugs for the treatment of Alzheimer's disease. The most important agreements are the Development and Commercialization agreement for the lecanemab antibody, which was signed 2007, and the Development and Commercialization agreement for the antibody lecanemab back-up for Alzheimer's disease, which was signed 2015. In 2014, Eisai and Biogen entered into a joint development and commercialization agreement for lecanemab. Eisai is responsible for the clinical development, application for market approval and commercialization of the products for Alzheimer's disease. BioArctic has the right to commercialize lecanemab in the Nordic region and is currently preparing for commercialization in the Nordics together with Eisai. BioArctic has no development costs for lecanemab in Alzheimer's disease and is entitled to payments in connection with sales milestones as well as royalties on global sales.

About BioArctic AB

BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company invented Leqembi® (lecanemab) – the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with BioArctic's partner Eisai, who are responsible for regulatory interactions and commercialization globally. In addition to Leqembi, BioArctic has a broad research portfolio with antibodies against Parkinson's disease and ALS as well as additional projects against Alzheimer's disease. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which has the potential to actively transport antibodies across the blood-brain barrier to enhance the efficacy of the treatment. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For further information, please visit www.bioarctic.com.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/bioarctic/r/new-clinical-and-real-world-evidence-on-lecanemab-to-be-presented-at-aaic-conference-2026,c4368866

The following files are available for download:

https://mb.cision.com/Main/9978/4368866/4172612.pdf

​​​​​​​New clinical and real-world evidence on Lecanemab to be presented at AAIC conference 2026

 

 

View original content:https://www.prnewswire.com/news-releases/new-clinical-and-real-world-evidence-on-lecanemab-to-be-presented-at-aaic-conference-2026-302814187.html

SOURCE BioArctic

FAQ

What did BioArctic (B) announce about lecanemab presentations at AAIC 2026?

BioArctic announced that partner Eisai will present broad new data on lecanemab at AAIC 2026. According to BioArctic, sessions will cover subcutaneous dosing, long-term use, maintenance regimens, at-home administration, and multiple clinical and real-world studies in Alzheimer’s disease.

Which lecanemab subcutaneous data will be shown at AAIC 2026 for BioArctic (B)?

Eisai will present emerging clinical evidence and practical use considerations for subcutaneous lecanemab in early Alzheimer’s disease. According to BioArctic, this includes findings from clinical trials and real-world patient experience, discussed in a dedicated Developing Topics Session on July 12, 2026.

What is the LEADER real-world lecanemab study highlighted by BioArctic (B)?

The LEADER study is a multicenter, real-world, retrospective analysis of lecanemab use in diverse US clinical settings. According to BioArctic, AAIC 2026 data will include maintenance dosing with IV infusions every four weeks and first reported at-home subcutaneous administration findings.

How is BioArctic (B) involved in preclinical Alzheimer’s research at AAIC 2026?

Preclinical Alzheimer’s research will feature the Phase 3 AHEAD 3-45 lecanemab study. According to BioArctic, AAIC 2026 presentations will provide progress updates, including participant retention and engagement, helping investors understand how lecanemab is being evaluated earlier in the Alzheimer’s disease continuum.

What additional lecanemab oral presentations related to BioArctic (B) will appear at AAIC 2026?

Additional talks will address ARIA management, sex-based outcomes, external control groups, tau biomarker modulation, tau PET changes, and racial and ethnic biomarker differences. According to BioArctic, these sessions use data from studies such as Clarity AD and other lecanemab clinical and observational programs.

What poster and symposium activities on lecanemab involve BioArctic (B) at AAIC 2026?

AAIC 2026 includes numerous lecanemab posters on real-world outcomes, subcutaneous initiation, safety, economic impact, and caregiver burden. According to BioArctic, Eisai will also host a healthcare-professional symposium titled “Early Intervention in Alzheimer’s Disease: Building the Evidence from Pathology to Practice” on July 14.